Skip to main content

Advertisement

SpringerLink
Log in

Effect of dapagliflozin on the triglyceride-glucose index and the atherogenic index of plasma used as markers of atherosclerosis in patients with type 2 diabetes mellitus

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Objective

Atherogenic index of plasma (AIP) and triglyceride-glucose (TyG) index are inexpensive and non-invasive markers with high predictive value for early detection of cardiovascular disease in DM patients. Herein, dapagliflozin reduced the AIP and TyG and caused positive cardiovascular effects in patients with type 2 diabetes mellitus (T2DM).

Methods

We retrospectively evaluated the data of patients aged >18 years with T2DM (n = 348; 210 [60.3%] women and 138 [37.7%] men; mean age = 59.24, standard deviation [SD] = ±10.44 years) who presented to a single-center internal medicine outpatient clinic between June 01, 2017, and December 30, 2020, and who were started on dapagliflozin as part of their treatment. Demographic data and clinical data of the patients at 0, 6, 12, and 24 months were retrieved from the electronic medical records of the hospital.

Results

Hypertension was the most common comorbidity (n = 155 [48.9%] patients). AIP values measured before dapagliflozin initiation (mean = 0.68; SD, 0.33) and at 6 months (mean = 0.62; SD, 0.30) were significantly different (p < 0.00). Furthermore, TyG index values measured before initiation of medication (mean = 9.98; SD, 0.76) and at 6 months (mean = 9.73; SD, 0.71) were significantly different (p < 0.00). These differences persisted until 12 and 24 months after treatment initiation.

Conclusions

Dapagliflozin administration lowered the AIP and TyG index in patients with T2DM; this may slow the atherosclerotic process and prevent the associated macrovascular complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. https://doi.org/10.1016/j.diabres.2013.11.002.

    Article  CAS  PubMed  Google Scholar 

  2. Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. https://doi.org/10.1056/NEJMoa1008862. Erratum in: N Engl J Med. 2011 Mar 31;364(13):1281.

  3. Wu QL, Zheng T, Li SZ, et al. Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2022;14:41. https://doi.org/10.1186/s13098-022-00810-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Briand F, Mayoux E, Brousseau E, Burr N, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–8. https://doi.org/10.2337/db16-0049.

    Article  CAS  PubMed  Google Scholar 

  5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.

    Article  CAS  PubMed  Google Scholar 

  6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.

    Article  CAS  PubMed  Google Scholar 

  7. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.

    Article  CAS  PubMed  Google Scholar 

  8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.

    Article  CAS  PubMed  Google Scholar 

  9. Solomon SD, McMurray JJ, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.

    Article  PubMed  Google Scholar 

  10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–421.

    Article  PubMed  Google Scholar 

  11. Nwagha UI, Ikekpeazu EJ, Ejezie FE, et al. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci. 2010;10(3):248–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Cai G, Shi G, Xue S, et al. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):e8058.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Vasques ACJ, Novaes FS, da Saúde de Oliveira M, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98-e100. https://doi.org/10.1016/j.diabres.2011.05.030.

  14. Onat A, Can G. Kaya H et al index of plasma” (log10 triglyceride/high-density lipoprotein−cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4(2):89–98. https://doi.org/10.1016/j.jacl.2010.02.005.

    Article  PubMed  Google Scholar 

  15. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304. https://doi.org/10.1089/met.2008.0034.

    Article  CAS  PubMed  Google Scholar 

  16. Alizargar J, Bai CH, Hsieh NC, et al. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients[J]. Cardiovasc Diabetol. 2020;19(1):8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang A, Tian X, Zuo Y, et al. Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study. Cardiovasc Diabetol. 2021;20(1):113. https://doi.org/10.1186/s12933-021-01305-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ganbaatar B, Fukuda D, Shinohara M, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040. https://doi.org/10.1016/j.ejphar.2020.173040.

    Article  CAS  PubMed  Google Scholar 

  19. Liu Y, Xu J, Wu M, et al. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity. Lipids Health Dis. 2021;20:5. https://doi.org/10.1186/s12944-021-01430-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8:418–35. https://doi.org/10.1016/S2213-8587(20)30038-3.

    Article  CAS  PubMed  Google Scholar 

  21. Imre E, Gunhan HG, Erel P et al. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study. Minerva Endocrinol (Torino). 2021. https://doi.org/10.23736/S2724-6507.21.03465-5.

  22. Ertugrul DT, Kan E, Tura CB, et al. Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes. Int J Diabetes Dev Ctries. 2022;42(1):147–60.

    Article  CAS  Google Scholar 

Download references

Funding

The research was carried out by the initiative of the authors without investing.

Author information

Authors and Affiliations

  1. Departman of İnternal Medicine, Mersin City Training and Research Hospital, Mersin, Turkey

    Deniz Gezer, Semra Özkan Öztürk & Zehra Kocaman

  2. Mersin City Research and Education Hospital, Mersin, Turkey

    Deniz Gezer

Authors
  1. Deniz Gezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Semra Özkan Öztürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zehra Kocaman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DENİZ G, SEMRA ÖÖ, and ZEHRA K were involved in original all articles, applying eligibility criteria, and identifying original articles. All authors contributed extensively to manuscript writing, figure and table design, and revision.

Corresponding author

Correspondence to Deniz Gezer.

Ethics declarations

Ethical clearance

This study was approved by Mersin University Non-Interventional Clinical Research Ethics Committee (Decision date/No: 2023/291) and conducted in accordance with the Declaration of Helsinki and Human Rights. Before the survey, participants provided electronic informed consent and were informed of their right to withdraw without explanation.

Informed consent

Informed consent was obtained from all the subjects online.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gezer, D., Öztürk, S.Ö. & Kocaman, Z. Effect of dapagliflozin on the triglyceride-glucose index and the atherogenic index of plasma used as markers of atherosclerosis in patients with type 2 diabetes mellitus. Int J Diabetes Dev Ctries (2023). https://doi.org/10.1007/s13410-023-01246-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13410-023-01246-9

Keywords

Search

Navigation